Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies
ConclusionCemiplimab exhibited antitumor activity in Japanese patients with advanced malignancies. The safety profile was comparable to those previously reported for cemiplimab and other PD-1 inhibitors.Trial registrationNCT03233139 at ClinicalTrials.gov.Graphic abstract
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Chemotherapy | Dermatitis | Dermatology | Drugs & Pharmacology | Japan Health | Respiratory Medicine | Study | Toxicology